Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 97

1.

Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.

Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR.

Am J Hematol. 2016 Feb;91(2):179-84. doi: 10.1002/ajh.24223. Epub 2015 Nov 26.

2.

Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.

Gupta M, Stenson M, O'Byrne M, Maurer MJ, Habermann T, Cerhan JR, Weiner GW, Witzig TE.

Ann Oncol. 2016 Jan;27(1):165-72. doi: 10.1093/annonc/mdv486. Epub 2015 Oct 20.

PMID:
26487586
3.

Engineering Rhodosporidium toruloides for increased lipid production.

Zhang S, Skerker JM, Rutter CD, Maurer MJ, Arkin AP, Rao CV.

Biotechnol Bioeng. 2015 Oct 19. doi: 10.1002/bit.25864. [Epub ahead of print]

PMID:
26479039
4.

Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

Ghesquieres H, Slager SL, Jardin F, Veron AS, Asmann YW, Maurer MJ, Fest T, Habermann TM, Bene MC, Novak AJ, Mareschal S, Haioun C, Lamy T, Ansell SM, Tilly H, Witzig TE, Weiner GJ, Feldman AL, Dogan A, Cunningham JM, Olswold CL, Molina TJ, Link BK, Milpied N, Cox DG, Salles GA, Cerhan JR.

J Clin Oncol. 2015 Nov 20;33(33):3930-7. doi: 10.1200/JCO.2014.60.2573. Epub 2015 Oct 12.

PMID:
26460308
5.

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES.

Oncotarget. 2015 Nov 3;6(34):35737-54. doi: 10.18632/oncotarget.5927.

6.

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.

Novak AJ, Asmann YW, Maurer MJ, Wang C, Slager SL, Hodge LS, Manske M, Price-Troska T, Yang ZZ, Zimmermann MT, Nowakowski GS, Ansell SM, Witzig TE, McPhail E, Ketterling R, Feldman AL, Dogan A, Link BK, Habermann TM, Cerhan JR.

Blood Cancer J. 2015 Aug 28;5:e346. doi: 10.1038/bcj.2015.69.

7.

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL, Goode EL.

Cancer Immunol Immunother. 2015 Dec;64(12):1495-504. doi: 10.1007/s00262-015-1753-x. Epub 2015 Aug 23.

PMID:
26298430
8.

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW.

J Clin Oncol. 2015 Aug 10;33(23):2516-22. doi: 10.1200/JCO.2014.59.7534. Epub 2015 Jun 29.

PMID:
26124482
9.

Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.

Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS.

Am J Hematol. 2015 Sep;90(9):790-5. doi: 10.1002/ajh.24086. Epub 2015 Jul 27.

PMID:
26096944
10.

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.

Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR.

Br J Haematol. 2015 Jul;170(1):85-95. doi: 10.1111/bjh.13399. Epub 2015 Apr 7.

PMID:
25851937
11.

Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.

Demosthenous C, Han JJ, Stenson MJ, Maurer MJ, Wellik LE, Link B, Hege K, Dogan A, Sotomayor E, Witzig T, Gupta M.

Oncotarget. 2015 Apr 20;6(11):9488-501.

12.

The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

Boddicker RL, Kip NS, Xing X, Zeng Y, Yang ZZ, Lee JH, Almada LL, Elsawa SF, Knudson RA, Law ME, Ketterling RP, Cunningham JM, Wu Y, Maurer MJ, O'Byrne MM, Cerhan JR, Slager SL, Link BK, Porcher JC, Grote DM, Jelinek DF, Dogan A, Ansell SM, Fernandez-Zapico ME, Feldman AL.

Blood. 2015 May 14;125(20):3118-27. doi: 10.1182/blood-2014-05-578575. Epub 2015 Apr 1.

PMID:
25833963
13.

Reply to V. Pitini et al and L.J. Costa.

Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Link BK.

J Clin Oncol. 2015 May 10;33(14):1625-6. doi: 10.1200/JCO.2014.60.5535. Epub 2015 Mar 23. No abstract available.

PMID:
25800767
14.

Plasma immune analytes in patients with epithelial ovarian cancer.

Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, Oberg AL, Knutson KL.

Cytokine. 2015 May;73(1):108-13. doi: 10.1016/j.cyto.2015.01.035. Epub 2015 Mar 3.

PMID:
25743245
15.

Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.

Bakkum-Gamez JN, Wentzensen N, Maurer MJ, Hawthorne KM, Voss JS, Kroneman TN, Famuyide AO, Clayton AC, Halling KC, Kerr SE, Cliby WA, Dowdy SC, Kipp BR, Mariani A, Oberg AL, Podratz KC, Shridhar V, Sherman ME.

Gynecol Oncol. 2015 Apr;137(1):14-22. doi: 10.1016/j.ygyno.2015.01.552. Epub 2015 Feb 10.

PMID:
25677060
16.

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.

Wahner Hendrickson AE, Hawthorne KM, Goode EL, Kalli KR, Goergen KM, Bakkum-Gamez JN, Cliby WA, Keeney GL, Visscher DW, Tarabishy Y, Oberg AL, Hartmann LC, Maurer MJ.

Gynecol Oncol. 2015 Apr;137(1):77-85. doi: 10.1016/j.ygyno.2015.01.539. Epub 2015 Jan 22.

PMID:
25620544
17.

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH.

Blood. 2015 Jan 22;125(4):658-67. doi: 10.1182/blood-2014-04-571786. Epub 2014 Dec 1.

18.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM.

Blood. 2015 Feb 5;125(6):992-8. doi: 10.1182/blood-2014-06-583369. Epub 2014 Nov 24.

19.

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC.

Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533. Epub 2014 Nov 14.

20.

Genetic diversity of newly diagnosed follicular lymphoma.

Asmann YW, Maurer MJ, Wang C, Sarangi V, Ansell SM, Feldman AL, Nowakowski GS, Manske M, Price-Troska T, Yang ZZ, Slager SL, Habermann TM, Cerhan JR, Novak AJ.

Blood Cancer J. 2014 Oct 31;4:e256. doi: 10.1038/bcj.2014.80. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk